ANYTIME NOW Q17 Mar 2022 12:18
From RNS 21st FEB
SDC-1801 (autoimmune diseases and severe Covid-19)
• Progress made advancing SDC-1801 towards clinical development as a potential treatment for autoimmune diseases and the acute respiratory symptoms of Covid-19
• Final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") were successfully completed in Q4 2021, and the final report is expected in Q1 2022
• Preliminary findings from these studies continue to support Sareum's plans to enter SDC-1801 into a first-in-human (Phase 1a) clinical study in healthy volunteers, and allow selection of an initial dose range